Wasatch Advisors LP acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 246,942 shares of the company's stock, valued at approximately $4,465,000. Wasatch Advisors LP owned about 0.36% of Phathom Pharmaceuticals at the end of the most recent quarter.
Several other large investors have also modified their holdings of PHAT. Huntington National Bank increased its position in Phathom Pharmaceuticals by 62.2% during the third quarter. Huntington National Bank now owns 1,471 shares of the company's stock worth $27,000 after buying an additional 564 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Phathom Pharmaceuticals by 41.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company's stock worth $43,000 after acquiring an additional 722 shares during the last quarter. US Bancorp DE raised its position in Phathom Pharmaceuticals by 28.6% in the 3rd quarter. US Bancorp DE now owns 5,248 shares of the company's stock valued at $95,000 after purchasing an additional 1,166 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Phathom Pharmaceuticals by 42.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,071 shares of the company's stock valued at $104,000 after purchasing an additional 2,987 shares during the last quarter. Finally, LVW Advisors LLC acquired a new stake in Phathom Pharmaceuticals during the 2nd quarter worth $133,000. Institutional investors and hedge funds own 99.01% of the company's stock.
Phathom Pharmaceuticals Price Performance
Shares of PHAT stock traded down $0.10 during trading hours on Friday, reaching $8.87. 423,267 shares of the company's stock were exchanged, compared to its average volume of 1,909,331. The company's 50 day moving average is $14.68 and its two-hundred day moving average is $13.31. The company has a market cap of $606.50 million, a P/E ratio of -1.56 and a beta of 0.72. Phathom Pharmaceuticals, Inc. has a 1 year low of $6.07 and a 1 year high of $19.71.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on PHAT shares. HC Wainwright reiterated a "buy" rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Monday, August 12th. The Goldman Sachs Group increased their price objective on Phathom Pharmaceuticals from $10.00 to $12.00 and gave the stock a "neutral" rating in a research report on Friday, August 9th. Finally, Needham & Company LLC restated a "buy" rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday, September 13th.
Check Out Our Latest Analysis on PHAT
About Phathom Pharmaceuticals
(
Free Report)
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Featured Articles
Before you consider Phathom Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.
While Phathom Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
